Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-18 5:10 pm Purchase |
2025-04-17 | 13D | Keros Therapeutics, Inc. KROS |
Pontifax Management 4 GP (2015) Ltd. | 4,787,331 11.800% |
52,824 (+1.12%) |
Filing History |
| 2025-04-11 8:32 pm Purchase |
2025-04-04 | 13D | Keros Therapeutics, Inc. KROS |
ADAR1 Capital Management, LLC | 5,390,964 13.290% |
5,390,964 (New Position) |
Filing History |
| 2025-02-14 4:12 pm Sale |
2024-12-31 | 13G | Keros Therapeutics, Inc. KROS |
ALKEON CAPITAL MANAGEMENT LLC | 1,101,000 2.700% |
-397,907 (-26.55%) |
Filing History |
| 2025-02-07 10:23 am Sale |
2025-01-31 | 13G | Keros Therapeutics, Inc. KROS |
FMR CORP | 704,472 1.700% |
-3,169,732 (-81.82%) |
Filing History |
| 2024-02-13 6:38 pm Purchase |
2023-12-31 | 13G | Keros Therapeutics, Inc. KROS |
ALKEON CAPITAL MANAGEMENT LLC | 1,498,907 5.000% |
106,505 (+7.65%) |
Filing History |
| 2024-02-09 09:16 am Purchase |
2024-02-08 | 13G | Keros Therapeutics, Inc. KROS |
FMR CORP | 3,874,204 12.931% |
195,115 (+5.30%) |
Filing History |
| 2024-01-26 5:26 pm Purchase |
2023-12-31 | 13G | Keros Therapeutics, Inc. KROS |
BLACKROCK INC BLK |
2,036,788 6.800% |
398,462 (+24.32%) |
Filing History |
| 2023-12-13 5:20 pm Unchanged |
2023-12-11 | 13D | Keros Therapeutics, Inc. KROS |
ORBIMED ADVISORS LLC | 1,268,734 4.200% |
0 (Unchanged) |
Filing History |
| 2023-02-14 09:53 am Sale |
2022-12-31 | 13G | Keros Therapeutics, Inc. KROS |
Deep Track Capital, LP | 0 0.000% |
-1,300,000 (Position Closed) |
Filing History |
| 2023-02-13 10:13 am Purchase |
2022-12-31 | 13G | Keros Therapeutics, Inc. KROS |
ALKEON CAPITAL MANAGEMENT LLC | 1,392,402 5.100% |
1,392,402 (New Position) |
Filing History |
| 2023-02-09 12:48 pm Purchase |
2023-02-09 | 13G | Keros Therapeutics, Inc. KROS |
FMR CORP | 3,679,089 13.357% |
174,291 (+4.97%) |
Filing History |
| 2023-02-07 11:06 am Purchase |
2022-12-31 | 13G | Keros Therapeutics, Inc. KROS |
BLACKROCK INC BLK |
1,638,326 5.900% |
351,800 (+27.34%) |
Filing History |
| 2023-02-02 2:23 pm Sale |
2023-01-26 | 13G | Keros Therapeutics, Inc. KROS |
Moshe Arkin | 1,371,074 4.980% |
-441,241 (-24.35%) |
Filing History |
| 2022-11-07 4:25 pm Unchanged |
2022-11-03 | 13D | Keros Therapeutics, Inc. KROS |
ORBIMED ADVISORS LLC | 1,268,734 4.600% |
0 (Unchanged) |
Filing History |
| 2022-04-12 06:18 am Unchanged |
2022-04-11 | 13G | Keros Therapeutics, Inc. KROS |
Moshe Arkin | 1,812,315 7.550% |
0 (Unchanged) |
Filing History |
| 2022-04-11 4:57 pm Sale |
2022-04-11 | 13G | Keros Therapeutics, Inc. KROS |
Moshe Arkin | 1,812,315 7.550% |
-223,825 (-10.99%) |
Filing History |
| 2022-02-14 08:58 am Purchase |
2021-12-31 | 13G | Keros Therapeutics, Inc. KROS |
Deep Track Capital, LP | 1,300,000 5.500% |
11,276 (+0.87%) |
Filing History |
| 2022-02-11 3:13 pm Sale |
2021-12-31 | 13G | Keros Therapeutics, Inc. KROS |
Foresite Capital Fund IV, L.P. | 0 0.000% |
-1,412,705 (Position Closed) |
Filing History |
| 2022-02-09 09:22 am Purchase |
2022-02-08 | 13G | Keros Therapeutics, Inc. KROS |
FMR CORP | 3,504,798 14.978% |
860,178 (+32.53%) |
Filing History |
| 2022-02-03 4:29 pm Purchase |
2021-12-31 | 13G | Keros Therapeutics, Inc. KROS |
BLACKROCK INC BLK |
1,286,526 5.500% |
87,325 (+7.28%) |
Filing History |